| Year |
Citation |
Score |
| 2020 |
Kendrick N, Powers G, Johansen J, Hoelter M, Koll A, Carlson S, Channaveerappa D, Darie CC. Preparation of a phosphotyrosine-protein standard for use in semiquantitative western blotting with enhanced chemiluminescence. Plos One. 15: e0234645. PMID 32555693 DOI: 10.1371/Journal.Pone.0234645 |
0.377 |
|
| 2020 |
Fowler AM, Salem K, DeGrave M, Ong IM, Rassman S, Powers GL, Kumar M, Michel CJ, Mahajan AM. Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer. Hormones & Cancer. PMID 31942683 DOI: 10.1007/S12672-020-00377-3 |
0.595 |
|
| 2018 |
Salem K, Kumar M, Yan Y, Jeffery JJ, Kloepping KC, Michel CJ, Powers GL, Mahajan AM, Fowler AM. Sensitivity and Isoform Specificity of F-Fluorofuranylnorprogesterone for Measuring Progesterone Receptor Protein Response to Estradiol Challenge in Breast Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30030339 DOI: 10.2967/Jnumed.118.211516 |
0.463 |
|
| 2018 |
Fowler A, Rassman S, DeGrave M, Ong I, Powers G, Salem K, Kumar M, Woo K, Mahajan A. Abstract PD8-07: Identifying steroid hormone receptor gene mutations in patients with newly diagnosed estrogen receptor positive metastatic breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd8-07 |
0.509 |
|
| 2017 |
Salem K, Kumar M, Powers GL, Jeffery JJ, Yan Y, Mahajan AM, Fowler AM. (18)F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer. Radiology. 162956. PMID 28956736 DOI: 10.1148/Radiol.2017162956 |
0.529 |
|
| 2017 |
Le B, Powers GL, Tam YT, Schumacher N, Malinowski RL, Steinke L, Kwon G, Marker PC. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer. Plos One. 12: e0174658. PMID 28350865 DOI: 10.1371/Journal.Pone.0174658 |
0.337 |
|
| 2016 |
Powers G, Su X, Beebe D, Marker P. Abstract B03: Developmental paracrine signaling pathways promote prostate cancer progression Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Devbiolca15-B03 |
0.398 |
|
| 2015 |
Powers GL, Hammer KD, Domenech M, Frantskevich K, Malinowski RL, Bushman W, Beebe DJ, Marker PC. Phosphodiesterase 4D inhibitors limit prostate cancer growth potential. Molecular Cancer Research : McR. 13: 149-60. PMID 25149359 DOI: 10.1158/1541-7786.Mcr-14-0110 |
0.409 |
|
| 2013 |
Powers GL, Rajbhandari P, Solodin NM, Bickford B, Alarid ET. The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene. Plos One. 8: e81110. PMID 24339902 DOI: 10.1371/Journal.Pone.0081110 |
0.718 |
|
| 2013 |
Lang JD, Berry SM, Powers GL, Beebe DJ, Alarid ET. Hormonally responsive breast cancer cells in a microfluidic co-culture model as a sensor of microenvironmental activity. Integrative Biology : Quantitative Biosciences From Nano to Macro. 5: 807-16. PMID 23559098 DOI: 10.1039/C3Ib20265H |
0.715 |
|
| 2013 |
Powers GL, Hammer KD, Su X, Domenech M, Beebe DJ, Marker PC. Abstract B22: The role of phosphodiesterase 4D and the microenvironment in prostate cancer Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-B22 |
0.399 |
|
| 2010 |
Powers GL, Ellison-Zelski SJ, Casa AJ, Lee AV, Alarid ET. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene. 29: 1509-18. PMID 19946334 DOI: 10.1038/Onc.2009.434 |
0.578 |
|
| 2008 |
Valley CC, Solodin NM, Powers GL, Ellison SJ, Alarid ET. Temporal variation in estrogen receptor-alpha protein turnover in the presence of estrogen. Journal of Molecular Endocrinology. 40: 23-34. PMID 18096994 DOI: 10.1677/Jme-07-0067 |
0.66 |
|
| Show low-probability matches. |